Dong-A Pharmaceutical's third-quarter sales of 2009 are expected to exceed 220 billion won.
Its quarter sales have never exceed 220 billion won since its foundation in 1932.
Sinji-won, analyst of Mirae Asset Securities Co., Ltd. expected on 28 September that Dong-A Pharmaceutical's third-quarter sales and operating profit would be 220.7 billion won and 29.8 billion won, up 17.8% and 18.5% respectively, compared with the same period of 2008.
He also said, "The Super antibiotic(DA-7181) which Dong-A Pharm has been developing has good reputation in the market. And its substitution effect in the world market is expected after 2015 when the patent of 'Zyvox' (Pfizer Inc.) will expire." [헬스코리아 뉴스]
◆ “동아제약, 3분기 매출액 2207억원...사상 최대치”
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
